Qilian International Holding Group Limited Received Approval for Export of Oxytetracycline APIs to Egypt
JIUQUAN, china, October 13, 2021 / PRNewswire / – Qilian International Holding Group Limited (Nasdaq: QLI) (the âCompanyâ), a Chinese pharmaceutical and chemical manufacturer, announced on September 14, 2021, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. . (the “Gansu QLS”), he has has received a pharmaceutical product certificate (the âExport Certificateâ) from the Gansu Province Drug Administration, which approves the export of its API Qilian ShanÂ® Oxytetracycline (active pharmaceutical ingredients) (the âAPIâ) to Egypt.
The export certificate indicates that the company’s API is a registered pharmaceutical product approved by China, complies with the relevant standards of China, is licensed to sell in the Chinese market and is not subject to any export restriction. In addition, the product is licensed for use and has already been used in the Egyptian market. Production facilities and operations also comply with the requirements of from China BPF.
Gansu QLS was established in 2006 and has grown to include the development, manufacture and sale of more than 20 pharmaceutical products, including three main ones, licorice products, oxytetracycline products and derivatives of traditional Chinese medicine (TCMD). These products have been sold in more than 20 provinces across China. Its oxytetracycline products also meet National Medical Products Administration (NMPA) certification, making them a strength of the company. In terms of revenue structure, oxytetracyclines are the Company’s primary sources of revenue. In recent performance periods, oxytetracycline and licorice products contributed over 60% of the Company’s revenues, while oxytetracycline products accounted for over 90% of this company’s sales. segment and constitute the Company’s flagship product.
Mr. Zhanchang Xin, Chairman and CEO of the company, said, âWe are very happy with this good news. The approval of this direct export license marks a smooth opening to foreign markets. This gives us a solid basis for future export expansion. in the future.”
About Qilian International Holding Group Limited
Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, products derived from traditional Chinese medicine, heparin products, casings of sausages and fertilizer. The Company’s products are sold to more than 20 provinces in China. For more information, visit the company’s website at http://qilianinternational.com/
This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections regarding future events and financial trends which, in the opinion of the Company, could affect its financial condition, results of operations and strategy. business, its financial needs and the successful construction of the pork by-product processing project facility. Investors may identify these forward-looking statements by words or expressions such as “may”, “will”, “expect”, “anticipate”, “aim”, “estimate”, “intend”, “plan” “,” Believe “,” potential “,” continue “,” is / are likely to “or other similar expressions. The Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as required by law. While the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee that such expectations will prove to be correct, and the Company cautions investors that actual results may differ materially from anticipated results and encourages investors to review other factors that may affect its future results in the company’s registration statement and in its other documents filed with the SEC.
For more information please contact:
Qilian International Holding Group Limited
E-mail: [emailÂ protected]
SOURCE Qilian International Holding Group Limited